Lanreotide
A depot somatostatin analog, similar in action to octreotide.
Identity
- Class
- Somatostatin analog (cyclic octapeptide)
- Source
- Synthetic analog of somatostatin
- Receptor
- Somatostatin receptors (SSTR2 and SSTR5 preferential)
Key properties
Molecular weight
~1,096.3 Da
Half-life (native)
depot-dominant (autogel acts over weeks)
Approximate values for the native hormone. Engineered analogs are often deliberately larger and far longer-acting.
Mechanism
Lanreotide is a somatostatin analog formulated as a long-acting depot (autogel) that releases over weeks, suppressing growth hormone and neuroendocrine secretion much like octreotide. Its prolonged depot kinetics are the practical contrast with the native peptide's minutes-long half-life.
Reference notes
- Delivered as an extended-release depot acting over weeks.
- Shares octreotide's SSTR2/5-preferential profile.
- Used in acromegaly and neuroendocrine tumors.
Selected literature
Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.
- 1.Acromegaly · Nature reviews. Disease primers, 2019 · PMID 30899019
- 2.Somatostatin Analogs in Clinical Practice: a Review · International journal of molecular sciences, 2020 · PMID 32121432